- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03607552
보충 스크리닝을 위한 비조영 DWI
치밀유방 여성의 추가 선별검사를 위한 비조영 DWI
Diffusion-weighted imaging (DWI) is a short (under 5 minutes) non-contrast MRI technique that has shown promise for the detection and characterization of breast cancer. Our preliminary data has shown that DWI holds potential for detecting mammographically and clinically-occult breast cancers. However, current technical limitations reduce the sensitivity of DWI for screening applications.
The identification of a screening tool to complement mammography that is more accurate than ultrasound and faster, less expensive, and safer than conventional contrast-enhanced MRI would have significant clinical impact by improving the early detection of cancer in women with dense breasts. We hypothesize that an optimized DWI approach will enable detection of mammographically occult breast cancer in women with dense breasts with high sensitivity and low false positive rate.
연구 개요
상세 설명
Hypothesis: With technical optimizations, non-contrast DWI can detect clinically and mammographically occult breast cancer in women with dense breasts with high sensitivity and low false positive rate.
Aim 1: Improve the breast DWI technique to maximize spatial resolution, reduce distortion, and increase lesion contrast.
- Develop novel DWI acquisition to increase spatial resolution and reduce distortion (using reduced field of-view and/or multishot echo planar imaging techniques)
- Identify optimal diffusion sensitization (b-value) to maximize conspicuity of cancers in women with dense breasts
Aim 2: Develop interpretation tools to optimize diagnostic performance for detecting cancer on DWI.
- Determine quantitative DWI thresholds (contrast-to-noise ratio, apparent diffusion coefficient [ADC]) that best differentiate benign and malignant lesions (i.e. maximize sensitivity and specificity)
- Develop computer aided assessment tools to facilitate clinical implementation and optimize reader accuracy
Aim 3: Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
- Conduct a controlled reader study of non-contrast DWI alone for breast cancer detection
- Perform receiver operating characteristic (ROC) analysis and determine the sensitivity and specificity for detection of mammographically occult cancer
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health & Science University
-
-
Washington
-
Seattle, Washington, 미국, 98109
- Seattle Cancer Care Alliance
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Women age 18+, with mammographically identified dense breasts, referred for clinical breast MRI
설명
Inclusion Criteria:
- Women aged 18 or older
- Dense breast identified on mammogram
Exclusion Criteria:
- Contra-indication to contrast-enhanced breast MRI (e.g. renal insufficiency with GFR<60, contrast allergy, incompatible metal)
- Patients who currently are undergoing chemoprevention therapy (e.g. aromatase inhibitors or selective estrogen receptor modulators)
- Women who are pregnant
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Phase 1: Pilot Study Phase
Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast. |
Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium. |
|
Phase 2: Development Phase
Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI. |
Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences. |
|
Phase 3: Reader Performance Phase
Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts. |
Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Diffusion sensitization (b value)
기간: 2.5 years
|
Identify optimal b value to maximize conspicuity of cancers in women with dense breasts |
2.5 years
|
|
Reader Interpretation strategy
기간: 3.5 years
|
Identify optimal ADC thresholds to differentiate malignant from benign lesions |
3.5 years
|
|
Specificity
기간: 4.5 years
|
Specificity will be assessed for non-contrast DWI |
4.5 years
|
|
Sensitivity
기간: 4.5 years
|
Sensitivity will be assessed for non-contrast DWI |
4.5 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Savannah Partridge, Fred Hutch/University of Washington Cancer Consortium
간행물 및 유용한 링크
일반 간행물
- Biswas D, Hippe DS, Wang Y, DelPriore MR, Zecevic M, Scheel JR, Rahbar H, Partridge SC. Accelerated Breast Diffusion-weighted Imaging Using Multiband Sensitivity Encoding with the CAIPIRINHA Method: Clinical Experience at 3 T. Radiol Imaging Cancer. 2022 Jan;4(1):e210063. doi: 10.1148/rycan.210063.
- Ha SM, Chang JM, Lee SH, Kim ES, Kim SY, Kim YS, Cho N, Moon WK. Detection of Contralateral Breast Cancer Using Diffusion-Weighted Magnetic Resonance Imaging in Women with Newly Diagnosed Breast Cancer: Comparison with Combined Mammography and Whole-Breast Ultrasound. Korean J Radiol. 2021 Jun;22(6):867-879. doi: 10.3348/kjr.2020.1183. Epub 2021 Apr 1.
- Oviedo F, Kazerouni AS, Liznerski P, Xu Y, Hirano M, Vandermeulen RA, Kloft M, Blum E, Alessio AM, Li CI, Weeks WB, Dodhia R, Lavista Ferres JM, Rahbar H, Partridge SC. Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection. Radiology. 2025 Jul;316(1):e241629. doi: 10.1148/radiol.241629.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 9785
- RG3017005 (기타 식별자: Fred Hutch/University of Washington Cancer Consortium)
- R01CA207290 (미국 NIH 보조금/계약)
- NCI-2020-05585 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .